Pub Date : 2025-12-19DOI: 10.1016/s1470-2045(25)00755-7
Manjulika Das
{"title":"Progress in global tobacco control measures","authors":"Manjulika Das","doi":"10.1016/s1470-2045(25)00755-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00755-7","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-19DOI: 10.1016/s1470-2045(25)00754-5
Tony Kirby
{"title":"Donated sperm with TP53 mutation used to conceive at least 197 children","authors":"Tony Kirby","doi":"10.1016/s1470-2045(25)00754-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00754-5","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-19DOI: 10.1016/s1470-2045(25)00753-3
Smriti Patodia
{"title":"San Antonio Breast Cancer Symposium 2025","authors":"Smriti Patodia","doi":"10.1016/s1470-2045(25)00753-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00753-3","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.1016/s1470-2045(25)00724-7
Talha Burki
No Abstract
没有抽象的
{"title":"UK Government launches first Men's Health Strategy","authors":"Talha Burki","doi":"10.1016/s1470-2045(25)00724-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00724-7","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-06DOI: 10.1016/s1470-2045(25)00594-7
Yi-Long Wu, Yu Yao, Jin-Ji Yang, Lin Wu, Wei Zhang, Ying Wang, Hai-Peng Xu, Yong Song, Yan Zhang, Jun Zhao, Jing-Hua Chen, Zhe-Hai Wang, Qi-Ming Wang, Jie Hu, Xing-Ya Li, Yun Fan, Yuan Chen, Jian Fang, Di Han, Wei-Zhe Xue, He-Peng Shi
<h3>Background</h3><em>MET</em> amplification is recognised as a de novo driver alteration in non-small-cell lung cancer (NSCLC) but treatment responses with existing MET inhibitors remain largely unsatisfactory. We aimed to investigate the antitumour activity and safety of vebreltinib, a potent and highly selective MET inhibitor, in patients with <em>MET</em> amplification-driven NSCLC.<h3>Methods</h3>KUNPENG was a multicentre, multi-cohort, single-arm, phase 2 trial conducted across 17 hospitals in China, in patients with locally advanced or metastatic NSCLC with <em>MET</em> dysregulation. Patients were eligible if they were MET inhibitor-naive, aged 18 years or older with <em>MET</em> amplification-driven NSCLC (gene copy number of six or higher), and progressed after previous standard chemotherapy or were ineligible for chemotherapy (cohort 2) or refused chemotherapy (cohort 3). Patients received 200 mg vebreltinib orally twice daily until disease progression or intolerable toxicity. The primary endpoint was the objective response rate, assessed by a masked independent review committee in the full analysis set. The study was amended to merge cohorts 2 and 3 due to slow accrual and was closed to enrolment on Nov 14, 2023. This trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span> (<span><span>NCT04258033</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>).<h3>Findings</h3>Between Jan 17, 2020, and Nov 14, 2023, 145 patients were enrolled; of these, 86 patients (30 chemotherapy-treated and 56 untreated) from cohorts 2 and 3 were included in the current analysis. The median age was 65 years (range 48–82; IQR 59–71), 77 (90%) patients were male, and nine (10%) were female. All patients were Chinese. 42 patients had partial response, resulting in an objective response rate of 48·8% (42 of 86; 95% CI 38·3–59·4) per masked independent review committee. The median follow-up was 18·6 months (IQR 15·7–37·3). The incidence of grade 3 or worse treatment-related adverse events was 31% (27 of 86), predominantly abnormal liver function terms reported by the investigators (eight [9%]). Serious adverse events related to treatment were reported by 16 (19%) patients. 11 treatment-emergent adverse events leading to death occurred, of which one patient died of abnormal liver function, which was possibly related to vebreltinib treatment.<h3>Interpretation</h3>Vebreltinib showed antitumour activity in patients with <em>MET</em> amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings.<h3>Funding<
{"title":"Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study","authors":"Yi-Long Wu, Yu Yao, Jin-Ji Yang, Lin Wu, Wei Zhang, Ying Wang, Hai-Peng Xu, Yong Song, Yan Zhang, Jun Zhao, Jing-Hua Chen, Zhe-Hai Wang, Qi-Ming Wang, Jie Hu, Xing-Ya Li, Yun Fan, Yuan Chen, Jian Fang, Di Han, Wei-Zhe Xue, He-Peng Shi","doi":"10.1016/s1470-2045(25)00594-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00594-7","url":null,"abstract":"<h3>Background</h3><em>MET</em> amplification is recognised as a de novo driver alteration in non-small-cell lung cancer (NSCLC) but treatment responses with existing MET inhibitors remain largely unsatisfactory. We aimed to investigate the antitumour activity and safety of vebreltinib, a potent and highly selective MET inhibitor, in patients with <em>MET</em> amplification-driven NSCLC.<h3>Methods</h3>KUNPENG was a multicentre, multi-cohort, single-arm, phase 2 trial conducted across 17 hospitals in China, in patients with locally advanced or metastatic NSCLC with <em>MET</em> dysregulation. Patients were eligible if they were MET inhibitor-naive, aged 18 years or older with <em>MET</em> amplification-driven NSCLC (gene copy number of six or higher), and progressed after previous standard chemotherapy or were ineligible for chemotherapy (cohort 2) or refused chemotherapy (cohort 3). Patients received 200 mg vebreltinib orally twice daily until disease progression or intolerable toxicity. The primary endpoint was the objective response rate, assessed by a masked independent review committee in the full analysis set. The study was amended to merge cohorts 2 and 3 due to slow accrual and was closed to enrolment on Nov 14, 2023. This trial is registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT04258033</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>).<h3>Findings</h3>Between Jan 17, 2020, and Nov 14, 2023, 145 patients were enrolled; of these, 86 patients (30 chemotherapy-treated and 56 untreated) from cohorts 2 and 3 were included in the current analysis. The median age was 65 years (range 48–82; IQR 59–71), 77 (90%) patients were male, and nine (10%) were female. All patients were Chinese. 42 patients had partial response, resulting in an objective response rate of 48·8% (42 of 86; 95% CI 38·3–59·4) per masked independent review committee. The median follow-up was 18·6 months (IQR 15·7–37·3). The incidence of grade 3 or worse treatment-related adverse events was 31% (27 of 86), predominantly abnormal liver function terms reported by the investigators (eight [9%]). Serious adverse events related to treatment were reported by 16 (19%) patients. 11 treatment-emergent adverse events leading to death occurred, of which one patient died of abnormal liver function, which was possibly related to vebreltinib treatment.<h3>Interpretation</h3>Vebreltinib showed antitumour activity in patients with <em>MET</em> amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings.<h3>Funding<","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"122 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1016/s1470-2045(25)00593-5
Jacob D Lesinski, Jingbo Yi, Elizabeth Ghias, James L Fisher, Marissa G Baker, Adana A M Llanos, Charles R Rogers, Arbor J L Quist, Ashley S Felix, Electra D Paskett, Mohamed I Elsaid, David Richardson, Anjum Hajat, Debasish Sundi, Ann-Kathrin Eisfeld, Ashley E Rosko, Timothy M Pawlik, Samilia Obeng-Gyasi, Zobeida Cruz-Monserrate, William E Carson, Jesse J Plascak
Background
Despite overall reductions in high-income countries, cancer mortality rates for some cancer types are rising among working-age adults. This study aimed to generate cancer mortality rates by sex, cancer type, and detailed occupation among working-age adults in the USA.
Methods
Cancer deaths (ICD-10 codes C00–C99) from 2020 to 2023 among adults aged 20–64 years were obtained from Mortality Multiple Cause of Death data from the US National Center for Health Statistics and the National Vital Statistics System, and categorised by sex, occupation, age, and year, using 459 detailed US Census 2010 occupation codes and 23 major occupation groups. Population estimates by sex, age, year, and occupation were obtained from the annual American Community Survey and Decennial Censuses. Average annual, age-adjusted cancer mortality rates and 95% confidence intervals (CI) by sex, occupation, and 22 main cancer sites were tabulated and displayed in forest plots.
Findings
The study was conducted from March 15, 2022, to August 27, 2025. Among 450 453 total cancer deaths, the average annual age-adjusted cancer mortality rate per 100 000 working-age US residents was 55·2 (95% CI 54·9–55·5) among males and 49·1 (48·8–49·4) among females. The highest overall mortality rates per 100 000 by detailed occupations shared across both sexes were fishing and hunting workers, with rates of 167·4 (95% CI 152·4–183·7) for males and 143·9 (99·1–204·6) for females; mining machine operators with rates of 126·6 (114·6–139·7) for males and 127·0 (65·7–235·8) for females; funeral directors with rates of 112·7 (87·9–148·7) for males and 152·8 (111·9–206·6) for females; animal trainers with rates of 117·3 (97·2–140·6) for males and 110·5 (92·6–130·8) for females; and dietitians and nutritionists with rates of 111·4 (83·8–145·8) for males and 105·6 (96·1–116·0) for females. 18 of 428 occupations accounted for 26·7% (66 521) of all male cancer deaths, and two of 377 occupations accounted for 6·5% (13 113) of all female cancer deaths.
Interpretation
US cancer mortality rates among working-age adults vary substantially by sex, occupation, and cancer site, suggesting workplace-related exposures beyond carcinogens. These findings highlight the need to study how working conditions, structural inequities, and health-care access influence cancer mortality risk by occupation.
{"title":"Cancer mortality rates by detailed occupation among US working-age adults between 2020 and 2023: a population-based study","authors":"Jacob D Lesinski, Jingbo Yi, Elizabeth Ghias, James L Fisher, Marissa G Baker, Adana A M Llanos, Charles R Rogers, Arbor J L Quist, Ashley S Felix, Electra D Paskett, Mohamed I Elsaid, David Richardson, Anjum Hajat, Debasish Sundi, Ann-Kathrin Eisfeld, Ashley E Rosko, Timothy M Pawlik, Samilia Obeng-Gyasi, Zobeida Cruz-Monserrate, William E Carson, Jesse J Plascak","doi":"10.1016/s1470-2045(25)00593-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00593-5","url":null,"abstract":"<h3>Background</h3>Despite overall reductions in high-income countries, cancer mortality rates for some cancer types are rising among working-age adults. This study aimed to generate cancer mortality rates by sex, cancer type, and detailed occupation among working-age adults in the USA.<h3>Methods</h3>Cancer deaths (ICD-10 codes C00–C99) from 2020 to 2023 among adults aged 20–64 years were obtained from Mortality Multiple Cause of Death data from the US National Center for Health Statistics and the National Vital Statistics System, and categorised by sex, occupation, age, and year, using 459 detailed US Census 2010 occupation codes and 23 major occupation groups. Population estimates by sex, age, year, and occupation were obtained from the annual American Community Survey and Decennial Censuses. Average annual, age-adjusted cancer mortality rates and 95% confidence intervals (CI) by sex, occupation, and 22 main cancer sites were tabulated and displayed in forest plots.<h3>Findings</h3>The study was conducted from March 15, 2022, to August 27, 2025. Among 450 453 total cancer deaths, the average annual age-adjusted cancer mortality rate per 100 000 working-age US residents was 55·2 (95% CI 54·9–55·5) among males and 49·1 (48·8–49·4) among females. The highest overall mortality rates per 100 000 by detailed occupations shared across both sexes were fishing and hunting workers, with rates of 167·4 (95% CI 152·4–183·7) for males and 143·9 (99·1–204·6) for females; mining machine operators with rates of 126·6 (114·6–139·7) for males and 127·0 (65·7–235·8) for females; funeral directors with rates of 112·7 (87·9–148·7) for males and 152·8 (111·9–206·6) for females; animal trainers with rates of 117·3 (97·2–140·6) for males and 110·5 (92·6–130·8) for females; and dietitians and nutritionists with rates of 111·4 (83·8–145·8) for males and 105·6 (96·1–116·0) for females. 18 of 428 occupations accounted for 26·7% (66 521) of all male cancer deaths, and two of 377 occupations accounted for 6·5% (13 113) of all female cancer deaths.<h3>Interpretation</h3>US cancer mortality rates among working-age adults vary substantially by sex, occupation, and cancer site, suggesting workplace-related exposures beyond carcinogens. These findings highlight the need to study how working conditions, structural inequities, and health-care access influence cancer mortality risk by occupation.<h3>Funding</h3>None.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"134 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1016/s1470-2045(25)00721-1
Emma Wilkinson
{"title":"UK–US drug pricing deal to cost NHS £3 billion as NICE increases new medicines threshold","authors":"Emma Wilkinson","doi":"10.1016/s1470-2045(25)00721-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00721-1","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145689509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/s1470-2045(25)00526-1
Andrea L Cheville, Jeph Herrin, Deirdre R Pachman, Veronica Grzegorczyk, Kurt Kroenke, Jennifer L Ridgeway, Sarah A Minteer, Jessica D Austin, Joan M Griffin, Linda Chlan, Cindy Tofthagen, Sandra A Mitchell, Ashley Smith, Kathryn J Ruddy
<h3>Background</h3>Patient-reported outcome measure (PROM) surveillance and collaborative care improve cancer symptom control. However, human resource requirements constrain their implementation and reach. Electronic health record (EHR) facilitation reduces resource needs and might allow population-level scaling. We aimed to assess the effect of EHR facilitation of PROM-directed collaborative care on clinical and health services outcomes.<h3>Methods</h3>E2C2 was a cohort cluster-randomised, unblinded, stepped-wedge, pragmatic trial, in which we randomly assigned 15 clusters of medical oncology and haematology clinics in the USA sharing a common EHR, Epic, to five sequences to compare an intervention of remotely delivered electronic PROM (ePROM) symptom surveillance and EHR-facilitated collaborative care (ECC) management with a usual care (UC) control of ePROM surveillance alone. Sequences transitioned from the UC control to the ECC intervention state at 8-month intervals. All adult (aged ≥18 years) patients who received medical oncology or haematology care in a US multi-state health system were enrolled. All cancer stages, cancer types, and treatment phases were included, except for patients enrolled in hospice or with acute leukaemia. SPPADE symptoms (sleep interference, pain, impaired physical function, anxiety, depression, and energy deficit or fatigue) were assessed with 0–10-point numerical rating scales linked to clinical encounters. The prespecified co-primary outcomes were all post-baseline SPPADE scores, and clinically actionable scores (≥4/10), among participants who completed at least two ePROMs. The outcomes were assessed using multivariate regression of cluster-period mean SPPADE symptom scores against intervention exposure, baseline SPPADE scores, fixed-cluster, and secular time effects. The trial is registered at <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span> (<span><span>NCT03892967</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>) and is now closed to recruitment.<h3>Findings</h3>From March 28, 2019, to Jan 31, 2023, 50 207 patients were enrolled and administered ePROMs in association with oncology or haematology visits. In the analytical cohort of 24 874 participants, 10 390 (42%) were assigned ePROMS in both the ECC and UC periods. Of the 19 084 [77%] in the ECC group, 11 138 (58%) were female, 7946 (42%) were male, and 18189 (95%) were White; and of the 16 180 (65%) in the UC group, 9621 (60%) were female, 6559 (40%) were male, and 15468 (96%) were White. 21 153 (85%) participants reported one or more clinically actionable symptoms (defined as SPPADE score ≥4/10). In multiva
{"title":"Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial","authors":"Andrea L Cheville, Jeph Herrin, Deirdre R Pachman, Veronica Grzegorczyk, Kurt Kroenke, Jennifer L Ridgeway, Sarah A Minteer, Jessica D Austin, Joan M Griffin, Linda Chlan, Cindy Tofthagen, Sandra A Mitchell, Ashley Smith, Kathryn J Ruddy","doi":"10.1016/s1470-2045(25)00526-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00526-1","url":null,"abstract":"<h3>Background</h3>Patient-reported outcome measure (PROM) surveillance and collaborative care improve cancer symptom control. However, human resource requirements constrain their implementation and reach. Electronic health record (EHR) facilitation reduces resource needs and might allow population-level scaling. We aimed to assess the effect of EHR facilitation of PROM-directed collaborative care on clinical and health services outcomes.<h3>Methods</h3>E2C2 was a cohort cluster-randomised, unblinded, stepped-wedge, pragmatic trial, in which we randomly assigned 15 clusters of medical oncology and haematology clinics in the USA sharing a common EHR, Epic, to five sequences to compare an intervention of remotely delivered electronic PROM (ePROM) symptom surveillance and EHR-facilitated collaborative care (ECC) management with a usual care (UC) control of ePROM surveillance alone. Sequences transitioned from the UC control to the ECC intervention state at 8-month intervals. All adult (aged ≥18 years) patients who received medical oncology or haematology care in a US multi-state health system were enrolled. All cancer stages, cancer types, and treatment phases were included, except for patients enrolled in hospice or with acute leukaemia. SPPADE symptoms (sleep interference, pain, impaired physical function, anxiety, depression, and energy deficit or fatigue) were assessed with 0–10-point numerical rating scales linked to clinical encounters. The prespecified co-primary outcomes were all post-baseline SPPADE scores, and clinically actionable scores (≥4/10), among participants who completed at least two ePROMs. The outcomes were assessed using multivariate regression of cluster-period mean SPPADE symptom scores against intervention exposure, baseline SPPADE scores, fixed-cluster, and secular time effects. The trial is registered at <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT03892967</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>) and is now closed to recruitment.<h3>Findings</h3>From March 28, 2019, to Jan 31, 2023, 50 207 patients were enrolled and administered ePROMs in association with oncology or haematology visits. In the analytical cohort of 24 874 participants, 10 390 (42%) were assigned ePROMS in both the ECC and UC periods. Of the 19 084 [77%] in the ECC group, 11 138 (58%) were female, 7946 (42%) were male, and 18189 (95%) were White; and of the 16 180 (65%) in the UC group, 9621 (60%) were female, 6559 (40%) were male, and 15468 (96%) were White. 21 153 (85%) participants reported one or more clinically actionable symptoms (defined as SPPADE score ≥4/10). In multiva","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145651224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01DOI: 10.1016/s1470-2045(25)00564-9
Kelly M Shaffer, Roger Anderson
No Abstract
没有抽象的
{"title":"The promise of scalable symptom surveillance with stepped collaborative care in oncology","authors":"Kelly M Shaffer, Roger Anderson","doi":"10.1016/s1470-2045(25)00564-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00564-9","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145657254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：